Osteoporosis Agents: Xgeva (denosumab) and Denosumab Biosimilars
Customize your policy alerts
Sign up for all Mass General Brigham Health Plan policy alerts
Know when Mass General Brigham Health Plan releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs medical-benefit prior authorization for denosumab products for MassHealth members, including prevention of skeletal-related events associated with bone metastases or multiple myeloma, treatment of hypercalcemia of malignancy, and treatment of giant cell tumor of bone.
Jubereq (denosumab-desu) was added as an additional preferred denosumab biosimilar.
Jubereq prior authorization requirements were added for both the pharmacy and medical benefits, and preferred-biosimilar criteria were updated.
Continuation criteria were updated to reflect MassHealth stability requirements.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.